Cantor Fitzgerald Maintains a Buy Rating on Aridis Pharmaceuticals Inc (ARDS)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Aridis Pharmaceuticals Inc (ARDS) today and set a price target of $25. The company’s shares opened today at $9.10.

Chen wrote:

“ARDS is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. We expect upward earnings revisions and multiple expansion to move ARDS’s stock higher. That should be driven by the successful advancement of ARDS’s pipeline. Valuation Summary We used a blend of DCF and EV/EBITDA analyses to arrive at our 12-month PT of $25.”

According to, Chen is a 4-star analyst with an average return of 10.3% and a 40.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Melinta Therapeutics Inc.

Aridis Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $28.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.85 and a one-year low of $7.59. Currently, Aridis Pharmaceuticals Inc has an average volume of 5,956.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.

From Our Partners